Seoul, South Korea, December 19, 2025 — MEDIPOST Co., Ltd., a fully integrated cell therapy biotechnology company, has entered into a multi-year exclusive commercialization license agreement with Teikoku Seiyaku Co., Ltd. to bring CARTISTEM®, its approved allogeneic stem cell therapy for knee osteoarthritis, to the Japanese market. The agreement includes an upfront payment of US$8 million, near-term regulatory milestones, and long-term sales-based incentives, positioning CARTISTEM® for expanded international adoption in one of the world’s most regulated and aging healthcare markets.
Science Significance
Scientifically, CARTISTEM® represents a landmark advancement in regenerative medicine for osteoarthritis, a condition historically managed with symptom-relief approaches rather than disease modification. CARTISTEM® is an allogeneic human umbilical cord blood–derived mesenchymal stem cell therapy designed to regenerate damaged cartilage in patients with moderate to severe knee osteoarthritis. Unlike conventional pharmacologic treatments, the therapy targets structural repair, supporting its potential classification as a disease-modifying osteoarthritis drug (DMOAD). With over 35,000 patients treated in South Korea since 2012, CARTISTEM® offers one of the most extensive real-world datasets among approved stem cell therapies.
Regulatory Significance
From a regulatory standpoint, the agreement underscores the maturation of cell therapy frameworks in Asia-Pacific markets. CARTISTEM® has already achieved regulatory approval in South Korea, providing a strong foundation of long-term safety and clinical performance data to support regulatory engagement in Japan. Under the agreement, MEDIPOST will retain manufacturing control and drug substance supply, ensuring compliance with stringent Japanese quality, traceability, and Good Manufacturing Practice (GMP) expectations. The inclusion of a short-term regulatory milestone reflects clear alignment with Japan’s structured approval and reimbursement pathways for advanced therapies.
Business Significance
Advertisement
Strategically, the partnership strengthens MEDIPOST’s global commercialization model while leveraging Teikoku Seiyaku’s established orthopedic hospital and clinic network across Japan. By granting exclusive sales, distribution, and promotion rights while retaining manufacturing ownership, MEDIPOST preserves long-term value capture and supply-chain control. For Teikoku Seiyaku, the agreement expands its orthopedic portfolio beyond traditional pharmaceuticals into high-value regenerative therapies, reinforcing its long-term growth strategy. The financial structure—combining upfront payment, regulatory milestones, and sales-based royalties—demonstrates strong commercial confidence in CARTISTEM®’s market potential.
Patients’ Significance
For patients, particularly in Japan’s rapidly aging population, the agreement has profound implications. Knee osteoarthritis is a leading cause of pain, disability, and reduced quality of life, often progressing to joint replacement surgery. CARTISTEM® offers a regenerative, minimally invasive alternative aimed at restoring cartilage rather than merely managing pain. Expanded access through Japan’s orthopedic care network could enable earlier intervention, delay or avoid surgery, and improve long-term mobility for patients with moderate to severe disease.
Policy Significance
At the policy level, the deal reflects growing government and healthcare system interest in regenerative medicine as a solution to chronic, age-related diseases. Japan has been a global leader in accelerated pathways for regenerative therapies, and partnerships like this align with national objectives to address unmet medical needs while managing the socioeconomic burden of musculoskeletal disorders. Successful commercialization of CARTISTEM® could further validate cell therapy reimbursement models and encourage broader adoption of regenerative approaches within public and private healthcare systems.
Overall, MEDIPOST’s exclusive licensing agreement with Teikoku Seiyaku marks a significant milestone in the international expansion of regenerative cell therapies. By combining proven clinical experience, robust manufacturing control, and local commercial expertise, the partnership positions CARTISTEM® to address a major unmet need in Japan’s knee osteoarthritis market. As regulatory and clinical momentum builds, the collaboration highlights how biopharma alliances can accelerate patient access to advanced, disease-modifying therapies while shaping the future of osteoarthritis treatment.
Source: MEDIPOST press release
